Immune Design Corp.

Immune Design Corp. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. The stock will provide you with a reasonable dividend income. Immune Design Corp. is not very popular among insiders. Tradey thinks it is not wise to invest in Immune Design Corp..
Log in to see more information.
Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approac...

News